Article

Immune-complex-like disease in the course of Enterobacter cloacae sepsis due to cholelithic cholecystitis preceded by influenza vaccination

Internal Medicine Ward of the Voivedship Hospital
Human Vaccines & Immunotherapeutics (Impact Factor: 3.64). 03/2012; 8(3):302-3. DOI: 10.4161/hv.18549
Source: PubMed

ABSTRACT This case report describes a 52-y-old male patient who, one week after influenza vaccination, presented with abdominal symptoms: pain in the right epigastrium followed by liver dysfunction and pyrexia, as well renal failure, muscles pain and consciousness disorders. Immune-complex-like disease and Enterobacter cloacae sepsis due to cholelithic cholecystitis were diagnosed. In this case, a correlation between vaccination and immune complex-like-disease was suspected based on the onset of symptoms a few days after vaccination and clinical improvement after plasmapheresis. The etiopathogenesis of immune-complex-like disease in this case possibly could relate to the similarity of the vaccine antigens and E. cloacae antigens as well a genetic predisposition.

Download full-text

Full-text

Available from: Małgorzata Sobieszczańska, Jul 18, 2014
0 Followers
 · 
91 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical trials evaluate a vaccine's safety before approval, but some risks may escape detection or adequate characterization until larger population exposures occur after licensure. To summarize reports of events occurring after vaccination with 7-valent pneumococcal conjugate vaccine (PCV), including those that may warrant further investigation to assess possible causation by PCV. Descriptive epidemiology of reports submitted to the Vaccine Adverse Event Reporting System (VAERS), a national passive surveillance database. United States during first 2 years after licensure of PCV (February 2000 through February 2002). Reports studied were for children younger than 18 years and vaccinated with PCV. Numbers and proportional distributions of reports. A total of 4154 reports of events following PCV were submitted to VAERS, for a rate of 13.2 reports per 100,000 doses distributed. Multiple vaccines were given in 74.3% of reports. The most frequently reported symptoms and signs included fever, injection site reactions, fussiness, rashes, and urticaria. Serious events were described in 14.6% of reports. There were 117 deaths, 23 reports of positive rechallenges, and 34 cases of invasive pneumococcal infections possibly representing vaccine failure. Immune-mediated events occurred in 31.3% of reports. All 14 patients with anaphylactic or anaphylactoid reactions survived. Thrombocytopenia developed in 14 patients and serum sickness in 6 others. Neurologic symptoms occurred in 38% of reports. Seizures described in 393 reports included 94 febrile seizures. The majority of reports to VAERS in the first 2 years after licensure of PCV described generally minor adverse events previously identified in clinical trials. The proportion of reports portraying serious events was similar to that for other vaccines. Although there are important limitations in passive surveillance data, and caution in their interpretation is necessary, symptoms experienced by a few children more than once after successive PCV doses, including allergic reactions, prolonged or abnormal crying, fussiness, dyspnea, and gastrointestinal distress, warrant continued surveillance, as do reports of rare but potentially serious events, such as seizures, anaphylactic or anaphylactoid reactions, serum sickness, and thrombocytopenia.
    JAMA The Journal of the American Medical Association 11/2004; 292(14):1702-10. DOI:10.1001/jama.292.14.1702 · 30.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: HB vaccine is one of the most widely administered vaccines in the world. Its efficacy approaches 95 per cent. The majority of adverse reactions are generally mild, although there have been individual case reports of serious reactions since the vaccine has become commercially available. Here, a patient with a serum sickness-like reaction after her second HB immunization is reported. Review of the literature for reports of serious adverse reactions to the vaccine was also carried out.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet 09/2002; 85 Suppl 2:S607-12.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ten patients developing a serum sickness-like hypersensitivity reaction to human diploid cell rabies vaccine were studied and compared with control subjects matched for previous vaccination history and level of rabies virus-specific IgG response to immunization. The clinical reaction consisted of delayed onset, generalized urticaria, and angioedema, with some arthralgias. Skin biopsy specimens demonstrated a leukocytoclastic vasculitis. Individuals reacting to the vaccine possessed IgE antibodies to human diploid cell rabies vaccine, to mock vaccine lacking viral antigen, and to fetal calf serum (FCS), a vaccine trace contaminant. Increased levels of IgG antibodies to FCS, mock vaccine, and beta-propiolactone-modified FCS, and human serum albumin were also found. Such humoral responses to vaccine components other than rabies virus might be responsible for the hypersensitivity reactions developing after rabies vaccination.
    Journal of Allergy and Clinical Immunology 05/1987; 79(4):605-10. DOI:10.1016/S0091-6749(87)80156-2 · 11.25 Impact Factor